Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers capsules, tablets, granules, and bulk drugs in the fields of cardiovascular, anti-infection, digestive system, nervous and mental system, hepatopathy, diabetes mellitus, etc., as well as liver disease, parenteral nutrition, first-aid, antibiotics, anesthesia, and tumor adjuvant. It is also developing nalmefene hydrochloride injection, dolasetron mesylate injection, cefodizime sodium for injection, hydroxyethyl starch and sodium chloride injection, medium and long chain fat emulsion injection, and compound amino acids injection. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Chengdu, China.
haisco pharmaceutical grou-a
(002653:Shenzhen Stock Exchange)
Taiwan Strait Technology Industry Development Park
No. 136, Baili Road
Phone: 86 89 3783 4865
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for 002653.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact HAISCO PHARMACEUTICAL GROU-A, please visit www.haisco.com. Company data is provided by Capital IQ. Please use this form to report any data issues.